PubMed: Antitumor Outcomes of Delta (9)-Tetrahydrocannabinol and Cannabinol on Cholangiocarcinoma Cells and Xenograft Mouse Styles

Evid Based mostly Complement Alternat Med. 2022 Nov 212022:6477132. doi: 10.1155/2022/6477132. eCollection 2022.

Abstract

Cholangiocarcinoma (CCA) is a quite intense tumor. The improvement of a new therapeutic drug for CCA is expected. This examine aims to assess the antitumor result of ∆⁹-tetrahydrocannabinol (THC), the key psychoactive part of marijuana (Cannabis sativa), and cannabinol (CBN), a minimal, lower-psychoactive cannabinoid, on CCA cells and xenograft mice. THC and CBN were isolated, and their identities had been verified by comparing ¹H- and ¹³C-NMR spectra and mass spectra with a databases. Cell proliferation, cell migration, and mobile apoptosis assays were carried out in HuCCT1 human CCA cells dealt with with THC or CBN. The phosphorylation of signaling molecules in HuCCT1 cells was detected. To figure out the outcomes of THC and CBN in an animal design, HuCCT1 cells have been inoculated subcutaneously into nude mice. Immediately after the tumors reached an appropriate dimensions, the mice had been dealt with with THC or CBN for 21 times. Tumor volumes had been monitored and calculated. The ¹H- and ¹³C-NMR details of THC and CBN were being nearly equivalent to these claimed in the literature. THC and CBN substantially inhibited mobile proliferation and migration and induced apoptosis in HuCCT1 cells. The phosphorylation of AKT, GSK-3α/β, and ERK1/2 lessened in HuCCT1 cells addressed with THC or CBN. CCA xenograft mice handled with THC showed substantially slower tumor progression and scaled-down tumor volumes than management mice. THC and CBN induced apoptosis in CCA by inhibiting the AKT and MAPK pathways. These findings give a powerful rationale for THC and CBN as therapeutic selections for CCA.

PMID:36452140 | PMC:PMC9705094 | DOI:10.1155/2022/6477132